Nordic Issuing

Ongoing case

Stayble Therapeutics AB

Back to all cases

Stayble Therapeutics AB

3 Feb - 17 Feb 2021Rights issue

Discogenic Chronic Low Back Pain (cLBP) is a disabling disease for patients, and an extremely expensive condition for society. Today, spinal fusion is the only available treatment for patients who do not respond to analgesics and physiotherapy. Stayble Therpeutics AB:s solution that has been evaluated in a clinical phase 1b trial, aims at changing that.

Stayble’s injectable formulation STA363 targets patients suffering from discogenic chronic low back pain who do not respond to conservative treatment such as analgesics and physiotherapy. STA363 not only offers patients an option when conservative treatment fails but also provides an alternative for patients who cannot afford, are not eligible or do not want to have spinal fusion surgery.

Read more on the company's website

The offer in summary

Record date: 29 January 2021

Subscription period: 3 February - 17 February 2021

Trading in subscription rights: 3 February – 15 February 2021

Terms: Shareholders in Euroclear by the record date 29 January 2021 will obtain one (1) subscription right per existing share. To subscribe for one (1) new share, one (1) subscription right are required to be exercised

Subscription price: SEK 6.00

Payment day: Payment and subscription form shall be Nordic Issuing at hand no later than 17 February 2021

Share ISIN: SE0013513652

Finacial adviser: Sedermera Fondkommission

Trading in BTA: 3 February 2021 - until the rights issue has been registered with the Swedish Companies Registration Office, which is expected to take place in the middle of March 2021

Those who on the record date of January 29, 2021 are registered as shareholders in Stayble Therapeutics AB have a preferential right to subscribe for shares in the current new share issue. For each existing share, one (1) subscription right is received. Each subscription right entitles the holder to subscribe for one (1) new share. The last day for trading in the share, including the right to receive subscription rights, is January 27, 2021. The first day for trading in the share, excluding the right to receive subscription rights, is January 28, 2021.

The offer comprises a maximum of 6,923,462 shares, corresponding to approximately MSEK 41.5.



Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.